January 3, 2018 / 9:39 PM / a year ago

BRIEF-Zynerba Pharmaceuticals Inc ‍Plans To Initiate Phase 2 Development Of ZYN001 In Tourette Syndrome By Year End ​

Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc:

* ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE

* ZYNERBA PHARMACEUTICALS INC - ‍PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018​

* ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019

* ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS​

* ZYNERBA - ‍IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES​

* ZYNERBA PHARMACEUTICALS INC - ‍PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below